Short Interest in Click Holdings Limited (NASDAQ:CLIK) Drops By 38.2%

Click Holdings Limited (NASDAQ:CLIK) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totaling 37,691 shares, a decrease of 38.2% from the June 15th total of 60,989 shares. Based on an average daily trading volume, of 123,258 shares, the days-to-cover ratio is presently 0.3 days. Approximately 3.3% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

CLIK has been the topic of several research reports. Weiss Ratings restated a “sell (d)” rating on shares of Click in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Click to a “hold” rating in a research note on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Click currently has an average rating of “Sell”.

Click Price Performance

Shares of CLIK stock opened at $1.73 on Friday. Click has a 52-week low of $1.32 and a 52-week high of $14.40. The company’s 50 day moving average is $1.60 and its 200 day moving average is $2.84.

Click (NASDAQ:CLIK) last posted its earnings results on Monday, May 11th. The company reported $0.10 earnings per share for the quarter. The company had revenue of $3.79 million for the quarter.

Institutional Investors Weigh In On Click

An institutional investor recently bought a new position in Click stock. Renaissance Technologies LLC bought a new stake in Click Holdings Limited (NASDAQ:CLIK) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click at the end of the most recent reporting period.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.